Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

10 Jan 2012 13:18

RNS Number : 3113V
Epistem Holdings plc
10 January 2012
 



Company Epistem Plc

TIDM EHP.L (AIM)

Headline Directors' Shareholdings

Released 10th January 2012

Number

 

 

 Epistem Holdings Plc ("Epistem" or the "Company")

 

Directors' Shareholdings & AGM

 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009

 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 297 ordinary shares of 1.5p each. These shares were acquired on 2 November 2011, 9 November 2011 and 23 December 2011 at prices of 383p, 383pand 358p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

 

Matthew Walls 8,965 (0.10%)

Dr Catherine Booth 983,320 (11.12%)

Dr Jeffrey Moore 15,645 (0.18%)

John Rylands 193,218 (2.18%)

 

Epistem further announces that all resolutions proposed at the Annual General Meeting held on 14 December 2011 were passed.

 

 

For further details please contact:

 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

 

Peel Hunt LLP

James Steel / Vijay Barathan +44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBXGDBIBBBGDG
Date   Source Headline
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSBusiness Update and SARS-COV-2 tests development
4th Mar 20203:33 pmRNSGrant of options
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results
11th Dec 20195:24 pmRNSHolding(s) in Company
11th Dec 201910:06 amRNSHolding(s) in Company
5th Dec 201911:30 amRNSAdditional Listing
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.